PDF(731 KB)
PDF(731 KB)
PDF(731 KB)
淮南市2018—2022年耐药肺结核流行特征分析
Analysis of the epidemiological characteristics of drug-resistant tuberculosis in Huainan from 2018 to 2022
目的 分析淮南市耐药肺结核的流行病学特征和趋势,为优化区域防控策略提供依据。方法 从中国疾病预防控制信息系统结核病信息管理系统提取2018年1月1日至2022年12月31日淮南市登记的全部耐药肺结核病例数据,采用SPSS 19.0进行描述性分析和χ2检验。结果 2018—2022年淮南市累计登记诊疗耐药肺结核患者249例,年平均登记发病率为1.51/10万,登记发病率变化趋势平稳(χ
Objective To analyze the epidemiological characteristics and trends of drug-resistant tuberculosis (DR-TB) in Huainan,and to provide evidence for optimizing regional prevention and control strategies. Methods The data of all DR-TB cases registered in Huainan from January 1,2018,to December 31,2022,were extracted from the Tuberculosis Information Management System of the China Disease Prevention and Control Information System.Descriptive analysis and chi-square tests were performed by using SPSS 19.0. Results A total of 249 DR-TB patients were registered and treated in Huainan from 2018 to 2022,and the average annual registered incidence rate was 1.51/100 000.The trend in registered incidence rate remained stable (χ
耐药肺结核 / 流行病学特征 / 登记发病率 / 耐多药结核病
Drug-resistant tuberculosis / Epidemiological characteristics / Registered incidence rate / Multidrug-resistant tuberculosis (MDR-TB)
| [1] |
Drug resistant tuberculosis contributes significantly to the global burden of antimicrobial resistance, often consuming a large proportion of the healthcare budget and associated resources in many endemic countries. The rapid emergence of resistance to newer tuberculosis therapies signals the need to ensure appropriate antibiotic stewardship, together with a concerted drive to develop new regimens that are active against currently circulating drug resistant strains. Herein, we highlight that the current burden of drug resistant tuberculosis is driven by a combination of ongoing transmission and the intra-patient evolution of resistance through several mechanisms. Global control of tuberculosis will require interventions that effectively address these and related aspects. Interrupting tuberculosis transmission is dependent on the availability of novel rapid diagnostics which provide accurate results, as near-patient as is possible, together with appropriate linkage to care. Contact tracing, longitudinal follow-up for symptoms and active mapping of social contacts are essential elements to curb further community-wide spread of drug resistant strains. Appropriate prophylaxis for contacts of drug resistant index cases is imperative to limit disease progression and subsequent transmission. Preventing the evolution of drug resistant strains will require the development of shorter regimens that rapidly eliminate all populations of mycobacteria, whilst concurrently limiting bacterial metabolic processes that drive drug tolerance, mutagenesis and the ultimate emergence of resistance. Drug discovery programs that specifically target bacterial genetic determinants associated with these processes will be paramount to tuberculosis eradication. In addition, the development of appropriate clinical endpoints that quantify drug tolerant organisms in sputum, such as differentially culturable/detectable tubercle bacteria is necessary to accurately assess the potential of new therapies to effectively shorten treatment duration. When combined, this holistic approach to addressing the critical problems associated with drug resistance will support delivery of quality care to patients suffering from tuberculosis and bolster efforts to eradicate this disease.
|
| [2] |
World Health Organization. Global Tuberculosis Report 2024[R/OL].(2025-03-14)[2025-04-10]. https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2024.
|
| [3] |
中国防痨协会. 耐药结核病化学治疗指南(2019年简版)[J]. 中国防痨杂志, 2019, 41(10):1025-1073.
|
| [4] |
赵雁林, 陈明亭. 中国结核病防治工作技术指南[M]. 北京: 人民卫生出版社, 2021.
|
| [5] |
向金凤, 杨小蓉. 2016—2022年绵阳市耐药肺结核患者流行病学特征分析[J]. 寄生虫病与感染性疾病, 2024,(1):27-30+36.
|
| [6] |
黎舒, 邱媛, 何波, 等. 2017—2021年南宁市耐多药肺结核的流行特征[J]. 广西医学, 2023, 45(5):580-584.
|
| [7] |
苏倩, 张婷. 重庆市2016—2020年耐药肺结核患者流行病学特征[J]. 中国热带医学, 2021, 21(10):948-951+964.
目的 分析2016—2020年重庆市耐药肺结核患者流行病学特征,为制定和完善全市耐药结核防控策略提供科学依据。方法 利用中国疾病预防控制信息系统的子系统—结核病管理信息系统资料, 通过描述流行病学方法,对 2016—2020 年重庆市耐药肺结核患者的时间、空间和人群分布进行统计分析。结果 2016—2020 年重庆市耐药肺结核患者3 255例,登记率为2.01/10万,呈逐年增加趋势(P<0.01),复治患者占70.45%(2 293/3 255),各年度初、复治构成比差异有统计学意义(P<0.01);地区分布以主城片区1 063例(占32.66%),各年度地区分布差异无统计学意义(P>0.05);中年组病例1 273例(占39.11%)和青年组1 207例(占37.08%)最高,各年度年龄组别差异有统计学意义(P<0.01);户籍类型中,流动人口2 187例(占67.19%),各年度户籍类型差异有统计学意义(P<0.01);职业以农民工、家政家务及待业为主,各年度职业分布有统计学差异(P<0.01);耐药患者登记分类以新患者(占29.55%)、复发(占27.53%)及初治失败(占22.12%)为主,各年度耐药患者登记分类差异有统计学意义(P<0.01)。结论 重庆市耐药结核疫情防控形势不容乐观。应加强全市耐药筛查和监测,重点关注主城区中青年流动人口结核病患者的宣教、诊疗和服药管理,优先对复治结核开展药敏检测,进一步完善耐药结核防控策略。
|
| [8] |
邓敏, 左真, 赵素荣, 等. 2015—2018年宜宾市耐多药肺结核疫情特征及治疗管理分析[J]. 寄生虫病与感染性疾病, 2020, 18(1):5-11+16.
|
| [9] |
余述凤, 梅晓冬, 阚晓宏, 等. 安徽省耐多药肺结核危险因素病例对照研究[J]. 中华疾病控制杂志, 2016, 20(10):1026-1028.
|
| [10] |
杨利, 常玥, 林海江. 2016—2021年台州市肺结核流行特征分析[J]. 预防医学, 2022, 34(11):1150-1155.
|
| [11] |
吴登俊, 丁守华. 淮安市耐多药肺结核疫情特征及治疗管理分析[J]. 江苏预防医学, 2018, 29(3):291-292.
|
| [12] |
刘凤英. 369例18—60岁男性结核病患病情况分析[J]. 中国伤残医学, 2016, 24(2):185-186.
|
| [13] |
许光辉, 赵柳婵, 张慧民, 等. 吸烟肺结核患者的临床特征分析[J]. 现代医院, 2016, 16(3):320-322.
|
| [14] |
张伟华, 杨轮, 苏文静, 等. 2011—2020年珠海市肺结核流行病学特征分析[J]. 现代预防医学, 2022, 49(14):2535-2538.
|
| [15] |
范大鹏, 岳永宁, 张艳, 等. 2014—2018年杭州市肺结核患者的耐药情况及其影响因素分析[J]. 中国防痨杂志, 2021, 43(1):72-79.
|
| [16] |
刘伟芝, 谭小英, 邱荣, 等. 江西省会昌县2019—2022年涂阳肺结核患者耐药影响因素分析[J]. 安徽预防医学杂志, 2024, 30(2):142-146.
|
利益冲突声明 所有作者声明无利益冲突
/
| 〈 |
|
〉 |